The sEV dose was determined from the volume of ascites and amount of tumor-derived sEV-VEGF in ascites that forms in mice at 3 weeks following i.p. injection of ES2 VEGF+/+ cells (Supplementary Fig. 9a, b). Here, VEGFA is linked to neoplasm.